Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 1,238 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,238 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $146,343.98. Following the sale, the chief financial officer now owns 71,471 shares in the company, valued at $8,448,586.91. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71.
• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The stock was sold at an average price of $119.09, for a total transaction of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $73,422.08.

Natera Stock Performance

Shares of Natera stock traded up $1.99 during trading hours on Wednesday, hitting $126.73. 794,882 shares of the company were exchanged, compared to its average volume of 1,316,621. Natera, Inc. has a 1 year low of $37.67 and a 1 year high of $133.54. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average of $123.31 and a 200-day moving average of $111.82. The stock has a market capitalization of $15.67 billion, a price-to-earnings ratio of -51.71 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s revenue was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.97) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NTRA shares. Robert W. Baird boosted their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Canaccord Genuity Group boosted their price objective on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a research report on Tuesday. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. Stephens reaffirmed an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.69.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Itau Unibanco Holding S.A. acquired a new stake in Natera in the second quarter valued at $28,000. Quarry LP grew its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC grew its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the last quarter. Tobam acquired a new stake in Natera in the second quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Natera in the first quarter valued at $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.